Soleus Capital Management, L.P. Iveric Bio, Inc. Transaction History

Soleus Capital Management, L.P.

  • $1.64 Billion
  • Q3 2025

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$18.67 - $24.56 $229,921 - $302,456
12,315 Added 0.58%
2,127,043 $51.8 Million
Q4 2022

Feb 14, 2023
SELL
$17.24 - $23.95 $6.69 Million - $9.29 Million
-387,873 Reduced 15.5%
2,114,728 $45.3 Million
Q3 2022

Nov 14, 2022
BUY
$9.4 - $18.59 $14.9 Million - $29.5 Million
1,588,255 Added 173.7%
2,502,601 $44.9 Million
Q2 2022

Aug 15, 2022
SELL
$9.12 - $18.9 $457,185 - $947,456
-50,130 Reduced 5.2%
914,346 $8.8 Million
Q1 2022

May 16, 2022
SELL
$12.15 - $16.83 $1.26 Million - $1.75 Million
-103,900 Reduced 9.73%
964,476 $16.2 Million
Q4 2021

Feb 14, 2022
SELL
$13.83 - $18.78 $340,826 - $462,814
-24,644 Reduced 2.25%
1,068,376 $17.9 Million
Q3 2021

Nov 15, 2021
SELL
$7.07 - $17.5 $12.1 Million - $30 Million
-1,715,323 Reduced 61.08%
1,093,020 $17.8 Million
Q2 2021

Aug 16, 2021
SELL
$5.69 - $7.17 $3.26 Million - $4.11 Million
-572,636 Reduced 16.94%
2,808,343 $17.7 Million
Q1 2021

May 17, 2021
BUY
$5.08 - $6.89 $9.06 Million - $12.3 Million
1,783,700 Added 111.67%
3,380,979 $20.9 Million
Q4 2020

Feb 16, 2021
SELL
$5.65 - $7.66 $500,590 - $678,676
-88,600 Reduced 5.26%
1,597,279 $11 Million
Q3 2020

Nov 13, 2020
BUY
$4.01 - $6.29 $237,303 - $372,229
59,178 Added 3.64%
1,685,879 $9.51 Million
Q2 2020

Aug 14, 2020
BUY
$3.06 - $6.6 $59,816 - $129,016
19,548 Added 1.22%
1,626,701 $8.3 Million
Q1 2020

May 15, 2020
BUY
$2.83 - $8.44 $2.66 Million - $7.92 Million
938,782 Added 140.46%
1,607,153 $5.53 Million
Q4 2019

Feb 14, 2020
BUY
$0.93 - $8.58 $621,585 - $5.73 Million
668,371 New
668,371 $5.73 Million

About IVERIC bio, Inc.

ISEE Quotes by TradingView
  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email